Johnson & Johnson
JNJ
$149.27
Share price
-0.43%
Change (1 day)
-8.35%
Change (1 year)
Categories
Johnson & Johnson is a global American pharmaceutical and consumer goods company with headquarters in New Brunswick, New Jersey. The company is listed in the Dow Jones Industrial Average.
Johnson & Johnson (JNJ) - Net assets
Net assets on the balance sheet as of December 2023 : $68.77 B
According to Johnson & Johnson's latest financial reports the company has $68.77 B in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Johnson & Johnson - Net assets on balance sheet (from 2001 to 2023)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2023-12-31 | $68.77 B | -10.46% |
| 2022-12-31 | $76.80 B | 3.76% |
| 2021-12-31 | $74.02 B | 16.98% |
| 2020-12-31 | $63.27 B | 6.4% |
| 2019-12-31 | $59.47 B | -0.47% |
| 2018-12-31 | $59.75 B | -0.68% |
| 2017-12-31 | $60.16 B | -14.57% |
| 2016-12-31 | $70.41 B | -1.03% |
| 2015-12-31 | $71.15 B | 2% |
| 2014-12-31 | $69.75 B | -5.81% |
| 2013-12-31 | $74.05 B | 14.23% |
| 2012-12-31 | $64.82 B | 13.57% |
| 2011-12-31 | $57.08 B | 0.89% |
| 2010-12-31 | $56.57 B | 11.84% |
| 2009-12-31 | $50.58 B | 19% |
| 2008-12-31 | $42.51 B | -1.87% |
| 2007-12-31 | $43.31 B | 10.18% |
| 2006-12-31 | $39.31 B | 1.57% |
| 2005-12-31 | $38.71 B | 21.68% |
| 2004-12-31 | $31.81 B | 18.4% |
| 2003-12-31 | $26.86 B | 18.38% |
| 2002-12-31 | $22.69 B | -6.34% |
| 2001-12-31 | $24.23 B |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $39.75 B | -42.19% | 🇨🇭 Switzerland |
 Pfizer PFE | $89.28 B | 29.83% | 🇺🇸 USA |
 Abbott Laboratories ABT | $38.82 B | -43.54% | 🇺🇸 USA |
 Medtronic MDT | $51.99 B | -24.40% | 🇮🇪 Ireland |
 Eli Lilly LLY | $10.86 B | -84.20% | 🇺🇸 USA |
 Sanofi SNY | $82.20 B | 19.53% | 🇫🇷 France |
 Gilead Sciences GILD | $22.74 B | -66.92% | 🇺🇸 USA |
 Stryker Corporation SYK | $18.59 B | -72.97% | 🇺🇸 USA |
 Merck MRK | $37.63 B | -45.28% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $16.28 B | -76.32% | 🇬🇧 UK |